Institutional members access full text with Ovid®

HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa

Hoffmann, Christopher Ja,b; Charalambous, Salomea; Fielding, Katherine Ld; Innes, Craiga; Chaisson, Richard Eb; Grant, Alison Dd; Churchyard, Gavin Ja,c,d

doi: 10.1097/QAD.0b013e32832e0585
Research Letters

In 2007, the WHO recommended a maximum stavudine dose of 30 mg. We compared virologic suppression among patients weighing more than 60 kg and receiving stavudine 30 mg (n = 110) versus 40 mg (n = 508) in community HIV clinics in South Africa, before and after guidelines changed. At 6 months, HIV RNA less than 400 copies/ml was achieved in 79% and 81% receiving 30 and 40 mg stavudine, respectively (χ2, P = 0.6). In regression modeling, including baseline HIV RNA and nonnucleoside reverse transcriptase inhibitor agent, stavudine dose remained unassociated with suppression.

aAurum Institute for Health Research, Johannesburg, South Africa

bJohns Hopkins School of Medicine, Baltimore, USA

cCentre for AIDS Research in South Africa, University of KwaZulu-Natal, Durban, South Africa

dLondon School of Hygiene and Tropical Medicine, London, UK.

Received 3 December, 2008

Revised 1 May, 2009

Accepted 5 May, 2009

© 2009 Lippincott Williams & Wilkins, Inc.